Monosan (Isosorbide Mononitrate)

Isosorbide Mononitrate, the active ingredient in Monosan, is an organic nitrate presented as an oral tablet for oral use. It is employed to relieve myocardial oxygen demand in patients with chronic stable angina and to help prevent angina attacks.

GNH USA supplies Monosan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isosorbide Mononitrate belongs to the organic nitrate class and is used in the management of angina‑related conditions.

Chronic stable angina pectoris: reduces the frequency and severity of angina episodes. Prevention of angina attacks: provides prophylactic relief to minimise sudden chest pain. Stable coronary artery disease: improves exercise tolerance by decreasing cardiac workload.

Isosorbide mononitrate may cause a range of adverse reactions, most of which are dose‑related and transient.

Common Side Effects: - Headache - Dizziness or light‑headedness - Flushing - Low blood pressure (hypotension) - Nausea - Palpitations

Serious or Rare Side Effects: - Severe hypotension leading to syncope - Acute myocardial infarction - Allergic reactions such as rash or angioedema - Methemoglobinemia (very rare) - Life‑threatening arrhythmias

Before initiating therapy, clinicians should evaluate cardiovascular status and consider potential drug interactions.

Assess cardiovascular status: confirm diagnosis of angina and evaluate blood pressure. Monitor blood pressure: check regularly, especially after dose changes. Review concomitant nitrate therapy: avoid using multiple nitrate products together. Avoid sudden posture changes: advise patients to rise slowly to reduce orthostatic hypotension. Adjust dose in hepatic impairment: consider lower starting dose if liver function is compromised. Store at room temperature: keep in the original container, protect from moisture and heat.

Isosorbide mononitrate can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid): - Other organic nitrates (risk of severe hypotension) - Phosphodiesterase‑5 inhibitors (e.g., sildenafil) – additive vasodilation - Alcohol (enhances blood‑pressure‑lowering effect) - Antihypertensive agents (may cause excessive hypotension) - Guanylate cyclase stimulators (potentiates vasodilatory response)

Moderate Interactions (Monitor Closely): - Diuretics (may increase risk of dehydration and hypotension) - Beta‑blockers (combined effect on heart rate and blood pressure) - Calcium‑channel blockers (additive cardiovascular effects) - ACE inhibitors or ARBs (enhanced blood‑pressure reduction) - Antiplatelet agents (monitor for bleeding risk)